These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19033369)

  • 21. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
    Kim SM; Yoo T; Lee SY; Kim EJ; Lee SM; Lee MH; Han MY; Jung SH; Choi JH; Ryu KH; Kim HT
    Life Sci; 2015 Oct; 139():166-74. PubMed ID: 26321528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
    Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
    Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
    Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
    Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
    Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
    Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
    Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
    Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
    Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
    Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of elagolix for the treatment of endometriosis.
    Melis GB; Neri M; Corda V; Malune ME; Piras B; Pirarba S; Guerriero S; Orrù M; D'Alterio MN; Angioni S; Paoletti AM
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):581-8. PubMed ID: 27021205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
    Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
    Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
    Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
    Stodtmann S; Nader A; Polepally AR; Suleiman AA; Winzenborg I; Noertersheuser P; Ng J; Mostafa NM; Shebley M
    Clin Transl Sci; 2021 Jul; 14(4):1611-1619. PubMed ID: 33963686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D; Masaki T; Tanaka A; Yoshimatsu M; Akinaga Y; Asada M; Sasada R; Takeyama M; Miwa K; Watanabe T; Kusaka M
    Eur J Pharmacol; 2014 Jan; 723():167-74. PubMed ID: 24333551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Li Y; Zheng Y; Xu B; Cai L; Feng S; Liu Y; Zhu Z; Yu Q; Guo H
    Clin Pharmacokinet; 2023 Dec; 62(12):1739-1748. PubMed ID: 37838623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
    Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
    J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
    Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.